Results 121 to 130 of about 958,637 (251)

Presenting JAK inhibitor safety information to dermatology patients

JEADV Clinical Practice
Janus Kinase (JAK) inhibitors are treatment options for dermatologic conditions such as atopic dermatitis, psoriasis, vitiligo, and alopecia areata. Guidance on how to counsel patients on these novel treatments is limited.
Anthony J. Teixeira, Jessica Q. Duong, Shirley P. Parraga, Steven R. Feldman   +3 more
doaj   +1 more source

Jak inhibitors in the treatment of alopecia areata - a literature review

Journal of Education, Health and Sport
Introduction Alopecia areata (AA) is a chronic autoimmune disorder causing non-scarring hair loss, which can range from isolated patches to complete scalp (alopecia totalis, AT) or body hair loss (alopecia universalis, AU).
Paulina Krzeszowska, Aleksandra Kujawa, Karolina Krochmal, Wojciech Pisarek, Adrianna Samoraj, Jakub Zajączkowski, Kacper Stępniak, Jan Wilk, Karolina Marrodán-Wojtczak, Radosław Kuźma   +9 more
doaj   +1 more source

Liver organoids: modelling complexity in homeostasis and disease

FEBS Letters, EarlyView.
Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley   +1 more source

Therapeutic effects of janus kinase inhibitors

Janus kinase (JAK) inhibitors are small synthetic molecules which can easily enter the intracellular space and inhibit janus kinases, which renders the janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway to be nonfunctional.
Ntwali, Arnaud
core  

JAK inhibitors in the management of extra-intestinal manifestations in inflammatory bowel disease

Therapeutic Advances in Gastroenterology
Extra-intestinal manifestations (EIMs) commonly occur in patients with inflammatory bowel diseases (IBD) and contribute significantly to morbidity and reduced quality of life. Their management remains challenging.
Fotios S. Fousekis, André Jefremow, Konstantinos H. Katsanos, Markus F. Neurath, Raja Atreya   +4 more
doaj   +1 more source

Effects of Janus Kinase Inhibitors on Rheumatoid Arthritis Pain: Clinical Evidence and Mechanistic Pathways

Biomedicines
Pain remains one of the most burdensome symptoms in rheumatoid arthritis (RA), often persisting despite inflammatory remission and profoundly impairing quality of life. This review aimed to evaluate the clinical efficacy and mechanistic pathways by which
Andrej Belančić, Seher Sener, Yusuf Ziya Sener, Almir Fajkić, Marijana Vučković, Antonio Markotić, Mirjana Stanić Benić, Ines Potočnjak, Marija Rogoznica Pavlović, Josipa Radić, Mislav Radić   +10 more
doaj   +1 more source

The microbiome in human skin aging

FEBS Letters, EarlyView.
Age‐related skin changes encompass the well‐known visible phenotypic alterations, together with microbiome dysbiosis and a series of molecular aging hallmarks. These hallmarks characterize not only a fully stablished aged phenotype but also the skin aging process itself.
Manuel Huerta Arana, Cornelia Wiegand, Omid Omrani, Mario Fabri   +3 more
wiley   +1 more source

A JAK gátlás lehetőségei az arthritisek kezelésében

, 2015
A JAK-inhibitorok klinikai hatékonyságának és biztonságosságának irodalmi összefoglalója rheumatoid arthritis megbetegedésekben, fókuszpontban a rheumatoid arthritis terápiájában elsőként elfogadott JAK-gátló, a tofacitinib (Xeljanz) készítménnyel.
Hamar, Attila
core  

Autophagy and mitophagy in pancreatic β‐cell homeostasis and their involvement in diabetes pathophysiology

FEBS Letters, EarlyView.
This review focuses on the role of autophagy and mitophagy in maintaining pancreatic β‐cell function and homeostasis. We discuss how genetic defects affecting these pathways contribute to the development of type 1, type 2, monogenic, and gestational diabetes. We further explore their potential as therapeutic targets. Created in BioRender.
Yunkyeong Lee, Mingming Tong, Anna L. Gloyn   +2 more
wiley   +1 more source

Golgi enzymes are retrieved from the plasma membrane to the trans‐Golgi network

FEBS Letters, EarlyView.
Golgi enzymes are traditionally considered resident proteins retained within the Golgi apparatus. Here, we demonstrate that a subset transiently reaches the cell surface and is subsequently retrieved to the trans‐Golgi network via retrograde transport. Using a nanobody‐based toolkit, we uncover a dynamic trafficking cycle of several Golgi enzymes.
Dominik P. Buser, Tina Junne
wiley   +1 more source